Myriad’s BRACAnalysis CDx® Test Identifies Patients with Ovarian Cancer Who Would Benefit from Second-Line Maintenance Treatment with Olaparib
Go back to Myriad’s BRACAnalysis CDx® Test Identifies Patients with Ovarian Cancer Who Would Benefit from Second-Line Maintenance Treatment with Olaparib| ASTRAZENECA PLC (NASDAQ: AZN) | Delayed: 92.77 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $92.77 | 52 Week High | $35.04 | |||
| Open | $92.77 | 52 Week Low | $26.97 | |||
| Day High | $92.77 | P/E | N/A | |||
| Day Low | $92.77 | EPS | $0.00 | |||
| Volume | 3,060,373 | |||||
| Myriad Genetics, Inc. (NASDAQ: MYGN) | Delayed: 3.89 -0.25 (6.04%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.14 | 52 Week High | $45.34 | |||
| Open | $4.15 | 52 Week Low | $15.92 | |||
| Day High | $4.17 | P/E | 1.67 | |||
| Day Low | $3.86 | EPS | $2.33 | |||
| Volume | 3,509,964 | |||||
